



Request for Letters of Intent

Collaborative Research Development Grant

2023 Grantees

Purpose

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Collaborative Research Development Grant. The purpose of this grantmaking program is to provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.

Eligibility and Selection Criteria

1. The Principal Investigator (one Principal Investigator must be selected) and other investigators must have full-time faculty appointments in a school of medicine or public health or recognized non-profit scientific research facility. They should not currently be in a training program. At least one key investigator must be a physician with expertise on ovarian cancer. International collaborations are welcome.
2. The selection committee will consider most favorably applications that are creative, original, and hold the most promise in the areas of screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics. Submissions that focus on health services research, quality of life, and epidemiology are also encouraged.
3. The primary review criteria will be the likelihood that the investigators can leverage this funding to establish a research team capable of performing high-impact research and competing successfully for additional funding.

If you have any questions about your eligibility, please contact us (see last page).

Terms of Grant

Support of up to \$300,000USD annually for three years (\$900,000USD total) will be granted to the institution(s) in which the recipients will conduct the research. Grant recipients will be required to submit activation deliverables and annual progress reports (narrative and financial) throughout the grant cycle. It is expected that the project will result in peer-reviewed publication(s). Any publications or presentations of work resulting from this grant should acknowledge support from OCRA

Selection Process

Letters of Intent will be reviewed by Ovarian Cancer Research Alliance's Scientific Advisory Committee (SAC), which is comprised of distinguished members of the medical, research and patient advocacy community from across the United States. The majority of LOIs will be triaged at this stage; only a fraction of those submitting LOIs will be invited to submit full proposals.

Timeline

The submission deadline for LOIs is 5:00pm ET on April 7, 2022. Late submissions and extension requests are not permitted. All applicants will be notified of their status in late May. For those selected to submit full proposals, full proposals will be due mid-June.

Application Process

Letters of Intent must be submitted in English via the [proposalCENTRAL website \(https://proposalcentral.com/GrantOpportunities.asp?GMID=99\)](https://proposalcentral.com/GrantOpportunities.asp?GMID=99) by 5:00pm ET on April 7, 2022.

The proposalCENTRAL website is easy to use and will lead you through the completion of the application. We recommend you log into the website soon and familiarize yourself with the website as well as the required parts of the LOI.

The LOI must include basic contact information for the applicant, as well as a scientific abstract of the proposed research project, which should be presented in 6,000 characters or less (including spaces), as well as biosketches for all investigators. No figures, references, appendices, budgets or letters of recommendation or collaboration are required or accepted at this stage. Approval for the care and use of animals in a laboratory setting will be verified at time of activation (do not include with LOI). Each candidate may submit only one LOI per cycle.

Answers to frequently asked questions about the application process are available online [here \(https://ocrahope.org/research/for-grantees/grant-application-faq/\)](https://ocrahope.org/research/for-grantees/grant-application-faq/).

Technical Support

If you are having technical problems with the proposalCENTRAL website, technical assistance is available from 8:30am – 5pm EST (GMT -4) by phone 800-875-2562 for toll-free in the U.S. and Canada or +1 703-964-5840 for direct dial international, and by email: pcsupport@altum.com.

Questions about the substantive aspects of the application should be directed to Kristin McGowan (contact info below).

About OCRA

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families. Visit ocrahope.org to learn more.

For inquiries or further information, please contact:

Kristin McGowan

Ovarian Cancer Research Alliance

14 Penn Plaza, Suite 2110

New York, NY 10122

Telephone: (212) 268-1002

Fax: (212) 947-5652

E-mail: grants@ocrahope.org



Request for Letters of Intent

Collaborative Research Development Grant – *Microsoft AI for Health*

2023 Grantees

Purpose

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Collaborative Research Development Grant in partnership with Microsoft AI for Health. The purpose of this grantmaking program is to provide funds for ovarian cancer research projects using AI or machine learning that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.

For this opportunity, OCRA is partnering with [Microsoft AI for Health](https://www.microsoft.com/en-us/ai/ai-for-health), a philanthropic program at Microsoft, which offers access to advanced Microsoft Azure cloud computing and collaboration with data science experts for nonprofits, academia, and researchers working on challenges in the area of health, including ovarian cancer. Investigators funded through this grant opportunity have access to support from Microsoft in the form of Azure computing credits, and in-kind data science support. This in-kind support from Microsoft will be in addition to the financial support from OCRA. For more information, follow this link: <https://www.microsoft.com/en-us/ai/ai-for-health>. For FAQs regarding this partnership between Microsoft and OCRA, please look under the Collaborative Research Development Grant section of the FAQs found here: <https://ocrahope.org/research/for-grantees/grant-application-faq/>.

Eligibility and Selection Criteria

1. The Principal Investigator (one Principal Investigator must be selected) and other investigators must have full-time faculty appointments in a school of medicine or public health or recognized non-profit scientific research facility. They should not currently be in a training program. At least one key investigator must be a physician with expertise on ovarian cancer. International collaborations are welcome.
2. The selection committee will consider most favorably applications that are creative, original, that leverage AI/machine learning, and that hold the most promise in the areas of screening and early detection, etiology and prevention, molecular therapeutics, cancer biology and genetics. Submissions that focus on health services research, quality of life, and epidemiology are also encouraged.
3. The primary review criteria will be the likelihood that the investigators can leverage this funding to establish a research team capable of performing high-impact research and competing successfully for additional funding, and leverage the resources provided through Microsoft AI for Health.

4. Investigators who wish to apply for the Collaborative Research Development Grant that do NOT have an AI focus or do not wish to partner with Microsoft AI for Health should apply through the other Collaborative Research Development Grant application, which is also available on ProposalCENTRAL.

If you have any questions about your eligibility, please contact us (see last page).

Terms of Grant

Support of up to \$300,000USD annually for three years (\$900,000USD total) will be awarded to the institution(s) in which the recipients will conduct the research. The CRDG-AI grant does require a partnership with Microsoft. If your grant does not have an AI component or you do not wish to partner with Microsoft AI for Health, you should apply for the CRDG and not the CRDG-AI. Grant recipients will be required to submit activation deliverables and annual progress reports (narrative and financial) throughout the grant cycle. It is expected that the project will result in peer-reviewed publication(s). Any publications or presentations of work resulting from this grant should acknowledge support from OCRA. *Successful applicants will contract directly with Microsoft for the support of that part of their project.*

Selection Process

Letters of Intent will be reviewed by Ovarian Cancer Research Alliance's Scientific Advisory Committee (SAC), which is comprised of distinguished members of the medical, research and patient advocacy community from across the United States. LOIs will also be reviewed by a small group from Microsoft, which will consider the proposed project's fit with Microsoft's AI for Health capabilities. After this initial review, a small group of semi-finalists will be selected. Each semi-finalist may have a brief phone call (approx. 30 minutes) with a member of the OCRA SAC and representatives from MS AI for Health to discuss the project. A small group of finalists will then be selected and asked to submit a full proposal. The final grantee will be selected by the OCRA SAC.

We recognize that preparing a full application represents a significant amount of time and energy for investigators, and we believe this process will ensure that only those applications most likely to be competitive advance to the final round of the competition.

Timeline

The submission deadline for LOIs is 5:00pm ET on April 7, 2022. Late submissions and extension requests are not permitted. All applicants will be notified of their status in late May. For those selected to submit full proposals, full proposals will be due mid-June.

Application Process

Letters of Intent must be submitted in English via the [proposalCENTRAL website](https://proposalcentral.com/GrantOpportunities.asp?GMID=99) (<https://proposalcentral.com/GrantOpportunities.asp?GMID=99>) by 5:00pm ET on April 7, 2022.

The proposalCENTRAL website is easy to use and will lead you through the completion of the application. We recommend you log into the website soon and familiarize yourself with the website as well as the required parts of the LOI.

The LOI must include basic contact information for the applicant, as well as a scientific abstract of the proposed research project, which should be presented in 6,000 characters or less (including spaces), as well as biosketches for all investigators.

Applicants must also complete the Supplementary Microsoft AI for Health document as an attachment. Please note that this document is made up of two parts: a fill-in application and a 2-3 page abstract. These parts must be combined and uploaded as one PDF into proposalCENTRAL for consideration.

No figures, references, appendices, budgets or letters of recommendation or collaboration are required or accepted at this stage. Approval for the care and use of animals in a laboratory setting will be verified at time of activation (do not include with LOI). Each candidate may submit only one LOI per cycle.

Answers to frequently asked questions specifically about the Microsoft AI for Health grant opportunity and the partnership between Microsoft and OCRA, please look under the Collaborative Research Development Grant section of the FAQs found here: <https://ocrahope.org/research/for-grantees/grant-application-faq/>.

Technical Support

If you are having technical problems with the proposalCENTRAL website, technical assistance is available from 8:30am – 5pm EST by phone 800-875-2562 for toll-free in the U.S. and Canada or +1 703-964-5840 for direct dial international, and by email: pcsupport@altum.com.

Questions about the substantive aspects of the application should be directed to Kristin McGowan (contact info below).

About OCRA

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families. Visit ocrahope.org to learn more.

For inquiries or further information, please contact:

Kristin McGowan
Ovarian Cancer Research Alliance
14 Penn Plaza, Suite 2110
New York, NY 10122
Telephone: (212) 268-1002
Fax: (212) 947-5652
E-mail: grants@ocrahope.org



Request for Letters of Intent

Early Career Investigator Grant

2023 Grantees

Purpose

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Early Career Investigator Grant (formerly called the Liz Tilberis Early Career Award). The Early Career Investigator Grant is for junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.

Eligibility and Selection Criteria

1. Applicants must be working in institutions with strong existing ovarian cancer research programs, in a school of medicine or public health, or a recognized non-profit scientific research facility.
2. Applicants should have strong training in preparation for an investigative career in ovarian cancer research and prior academic accomplishments.
3. The selection committee will consider most favorably applications that are creative, original, and hold the most promise in the areas of early detection, prevention, treatment, and translational ovarian cancer research. The proposed research plan should have sufficient scientific depth to allow the Early Career Investigator grantee to compete for additional funding after the period of this grant.
4. Candidates must have an MD/DO and/or PhD degree and should be in the first seven years of their first academic appointment after having completed their fellowship or post-doctoral training (Assistant Professor or equivalent). Individuals who will begin such a position by July 2022 are eligible for this award.
5. This year OCRA intends to prioritize funding for at least one clinician scientist for an Early Career Investigator Grant.
6. For MDs/DOs or MD/DO-PhDs with clinical responsibilities, at least 50% of the time must be dedicated to ovarian cancer research.
7. For applicants without clinical responsibilities, at least 75% of the time must be dedicated to ovarian cancer research.
8. Early Career Investigator Grants will not be granted to individuals who hold similar junior investigator awards from other funding agencies or foundations.
9. If invited to submit a full proposal, applicants will be required to provide two letters of recommendation, including one from someone in a position to mentor the applicant.

If you have questions about your eligibility, please contact us (see last page).

Terms of Award

Each Early Career Investigator grantee will receive a three-year grant of up to \$150,000USD per year (\$450,000USD total). Grant recipients will be required to submit activation deliverables and annual progress reports (narrative and financial) throughout the grant cycle. Any publications or presentations of work resulting from this grant should acknowledge support from OCRA.

Selection Process

Letters of Intent will be reviewed by the Ovarian Cancer Research Alliance's Scientific Advisory Committee (SAC), which is comprised of distinguished members of the medical, research and patient advocacy community from across the United States. The majority of LOIs will be triaged at this stage; only a fraction of those submitting LOIs will be invited to submit full proposals.

Timeline

The submission deadline for LOIs is 5:00pm ET on April 7, 2022. Late submissions and extension requests are not permitted. All applicants will be notified of their status in late May. For those selected to submit full proposals, full proposals will be due mid-June.

Application Process

Letters of Intent must be submitted in English via the [proposalCENTRAL website \(https://proposalcentral.com/GrantOpportunities.asp?GMID=99\)](https://proposalcentral.com/GrantOpportunities.asp?GMID=99) by 5:00pm EST on April 7, 2022.

The proposalCENTRAL website is easy to use, and will lead you through the completion of the application. We recommend you log into the website soon, and familiarize yourself with the website as well as the required parts of the application.

The LOI will include basic contact information for the applicant, biosketch, as well as a scientific abstract of the proposed research project, which should be presented in 6,000 characters or less. No figures, references, appendices, budgets or letters of recommendation or collaboration are required or accepted at this stage. Approval for the care and use of animals in a laboratory setting will be verified at time of activation (do not include with LOI). Each candidate may submit only one LOI per cycle.

Answers to frequently asked questions about the application process are available online [here \(https://ocrahope.org/research/for-grantees/grant-application-faq/\)](https://ocrahope.org/research/for-grantees/grant-application-faq/).

Technical Support

If you are having technical problems with the proposalCENTRAL website, technical assistance is available from 8:30am – 5pm ET by phone 800-875-2562 for toll-free in the U.S. and Canada or +1 703-964-5840 for direct dial international, and by email: pcsupport@altum.com.

Questions about the substantive aspects of the application should be directed to Kristin McGowan (contact info below).

About OCRA

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families. Visit ocrahope.org to learn more.

For inquiries or further information, please contact:

Kristin McGowan
Ovarian Cancer Research Alliance
14 Penn Plaza, Suite 2110
New York, NY 10122
Telephone: (212) 268-1002
Fax: (212) 947-5652
E-mail: grants@ocrahope.org

Request for Letters of Intent

Mentored Investigator Grant

2023 Grantees

Purpose

Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2023 Mentored Investigator Grant (formerly called the Schreiber Mentored Investigator Award). This grant provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research, or relevant area.

Eligibility and Selection Criteria

1. Applicants must be either clinical fellows or post-doctoral fellows with protected time to do the proposed work. Candidates for this grant must have an MD/DO and/or PhD degree.
2. Applicants must be working in institutions with well-developed ovarian cancer research programs, in a school of medicine or public health, or a recognized non-profit scientific research facility.
3. Applicants should be involved in either laboratory, clinical, epidemiologic or health services research. The research leader who will serve as the mentor should have significant independent cancer research funding (NCI, DOD, OCRA, etc.).
4. Each mentor may support only one applicant per year. We encourage research groups to vet concepts so that only one LOI is submitted for this award.
5. Submissions may only have one mentor listed.
6. PhD applicants must be no more than 5 years out of their terminal degree at time of application (e.g. terminal degree must have been awarded during 2017 or later); MD/DOs and MD/PhDs must be currently enrolled in a fellowship program.
7. This year OCRA intends to prioritize funding for proposals that span the entire range of Control and Population Sciences (CCPS), including (but not limited to): risk and outcome studies, survivorship, and health services research.
8. The selection committee will consider the strength of the research environment and project proposal, the trainee's prior academic track record, and the likelihood of his/her pursuing a research career dedicated to ovarian cancer. The research plan proposed should have sufficient scientific depth to potentially lead to publication of results in high quality journals, and should be able to be completed within the funding period (one or two years). Ideally, the project proposed should be one that the trainee's mentor believes will advance the overall scientific objectives of the research group.

If you have questions about your eligibility, please contact us (see last page).

Terms of Grant

The Mentored Investigator Grant provides a total of \$75,000USD to be used over one or two years. Although the trainee may take part in some non-research activities (e.g. class work, clinical activities), at least 80% effort should be devoted to research during the tenure of the OCRA grant.

It is the mentor's responsibility to assure that a trainee who receives this grant submits the required activation material and progress reports (narrative and financial) throughout the award cycle. Any publications or presentations of work resulting from this grant should acknowledge support from OCRA.

Selection Process

Letters of Intent will be reviewed by the Ovarian Cancer Research Alliance's Scientific Advisory Committee (SAC), which is comprised of distinguished members of the medical, research and patient advocacy community from across the United States. The majority of LOIs will be triaged at this stage; only a fraction of those submitting LOIs will be invited to submit full proposals.

Timeline

The submission deadline for LOIs is 5:00pm ET on April 7, 2022. Late submissions and extension requests are not permitted. All applicants will be notified of their status in late May. For those selected to submit full proposals, full proposals will be due in mid-June 2022.

Application Process

Letters of Intent must be submitted in English via the [proposalCENTRAL website](https://proposalcentral.com/GrantOpportunities.asp?GMID=99) (<https://proposalcentral.com/GrantOpportunities.asp?GMID=99>) by 5:00pm ET on April 7, 2022.

The proposalCENTRAL website is easy to use and will lead you through the completion of the LOI. We recommend you log into the website soon and familiarize yourself with the website as well as the required parts of the LOI.

The LOI includes basic contact information for the applicant, as well as a scientific abstract of the proposed research project, which should be presented in 6,000 characters or less (including spaces). The applicant's biosketch and the proposed mentor's biosketch are also required. No figures, references, appendices, budgets or letters of recommendation or collaboration are required or accepted at this stage. Approval for the care and use of animals in a laboratory setting will be verified at time of activation (do not include with LOI). Each candidate may submit only one LOI per cycle.

Answers to frequently asked questions about the application process are available online [here](https://ocrahope.org/research/for-grantees/grant-application-faq/) (<https://ocrahope.org/research/for-grantees/grant-application-faq/>).

Technical Support

If you are having technical problems with the proposalCENTRAL website, technical assistance is available from 8:30am – 5pm EST (GMT -4) by phone 800-875-2562 for toll-free in the U.S. and Canada or +1 703-964-5840, and by email: pcsupport@altum.com.

Questions about the substantive aspects of the application should be directed to Kristin McGowan (contact info below).

About OCRA

Ovarian Cancer Research Alliance (OCRA) is the leading organization in the world fighting ovarian cancer from all fronts, including in the lab and on Capitol Hill, while supporting women and their families. Visit ocrahope.org to learn more.

For inquiries or further information, please contact:

Kristin McGowan
Ovarian Cancer Research Alliance
14 Penn Plaza, Suite 2110
New York, NY 10122
Telephone: (212) 268-1002
Fax: (212) 947-5652
E-mail: grants@ocrahope.org